Все публикации

1:10:54

Driving New Discoveries in Myeloma Research with Dr. Brian Van Ness from the University of Minnesota

0:06:58

KarMMa Study: Immune Profiling in CAR-T Therapy for Myeloma | Bruno Paiva, PhD | #ASH24

0:02:36

MRD Status in Myeloma: Insights on Changes During Maintenance | Ross Firestone, MD, PhD | #ASH24

0:02:53

Myeloma 11 Trial: Carfilzomib Quadruplet Enhances Overall Survival | Charlotte Pawlyn, MD | #ASH24

0:03:25

Combination of Selinexor, Pomalidomide, & Dexamethasone for RRMM | Muhamed Baljevic, MD | #ASH24

0:04:14

Etentamig with Dexamethasone: Promising 2nd Line Therapy for RRMM | Muhamed Baljevic, MD | #ASH24

0:05:02

Talquetamab Efficacy & Toxicity in African American Myeloma Patients | Carolina Schinke, MD | #ASH24

0:05:58

ICAHT After CAR-T for Myeloma: a Stem Cell Boost Solution | Carolina Schinke, MD | #ASH24

0:04:24

Improving Myeloma Monitoring: Eliminating Sequential Tests | Jean Sebastien Claveau, MD | #ASH24

0:04:05

Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24

0:07:09

KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, MD | #ASH24

0:11:09

Side Effect Severity & Decision-Making Autonomy in Myeloma | Jay Hydren, PhD, CSCS | #ASH24

0:02:34

Myeloma Patient Experiences with Talquetamab | Jay Hydren, PhD, CSCS | #ASH24

0:03:52

Myeloma Updates: High-Risk Smoldering, MRD, IVIG, and Maintenance | Natalie Callander, MD | #ASH24

0:02:55

Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24

0:03:59

Study Shows Promise for Non-Invasive MRD Testing for Myeloma Patients | Dory Abelman PhD(c) | #ASH24

0:07:04

Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24

0:03:45

Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24

0:02:32

Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24

0:06:37

New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24

0:06:07

Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi & Erin Meermeier | #ASH24

0:06:00

Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24

0:01:54

Bone Marrow Spatial Signatures Predict Outcomes in R/R Myeloma Patients | Yoshinobu Konishi | #ASH24

0:02:44

Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics | Nadine Abdallah| #ASH24